Milotis has completed a clinical trial that paves the way for improving milk quality

The Israeli biopharmaceutical company Mileutis of Ness Ziona, which develops a biological preparation that is a substitute for the use of antibiotics, announced the completion of a rigorous, controlled and randomized clinical trial that was conducted among over 500 cows on seven different dairy farms throughout Israel. The results of the study clearly indicate the ability of the biological preparation Imilac™ developed by Milautis to replace the routine use of antibiotics in the dairy industry and to improve the quality and nutritional values of milk.

The most serious health problem of dairy cows is mastitis. In order to treat the frequency of this inflammation, antibiotics are now widely used, which causes the bacteria to increase their resistance. Milotis' Imilac™ preparation allows you to treat and prevent mastitis without the use of antibiotics. The clinical trials carried out by the company achieved results that change the rules of the game and lead the dairy industry to a sustainable future.

Milotis conducted a comprehensive experiment for over two years (including a full follow-up year) designed to analyze the quality and quantity of milk milked from cows treated with the preparation developed by the company, compared to the usual treatments based on antibiotics. The experiment was carried out in seven large dairy farms throughout Israel, from Kibbutz Yotbata and Hiel in the Arabah, through Moshav Kfar Vitkin in Emek Hefer to Emek Ma'aina in the north of the country. These farms supply milk to the largest milk producers in Israel: Strauss, partially owned by Danone, and Tnuva. The experiment revealed significant findings that support Milotis' goal of reducing the use of antibiotics in the dairy industry.

The Imilac demonstrated an impressive ability to significantly increase milk yield compared to nutritional values (ECM – Energy Corrected Milk) during the 305 days of subsequent lactation after treatment with the preparation. This increase amounted to 957 kg (8.6%) per cow and was achieved by natural biological means without hormones and without antibiotics. There was also an improvement in the quality of the milk, including an increase of 7.2% in protein and 4% in milk fat.

Also, the study proved that the use of Imilac™ makes it possible to shorten the "dry period" of cows and at the same time increase the number of milking days. This breakthrough resulted in an increase of 236 kg in the milk yield per cow, without the use of antibiotics. In addition, the preparation improves the well-being of the cows in the first days after the dry period.

David Javier Iskovic, CEO and co-founder, Mileutis: "Dairy farmers can look forward to the future outline of the industry where the milk they produce will have improved nutritional values, be more profitable and friendly to the environment and milk consumers – thanks to the pioneering innovation of Mileutis. Beyond the improvements in the health and well-being of the cows, the improvement in the profitability of the farm owners may affect milk prices and benefit the general public of consumers – while responding to the growing global demand for dairy products."

Iskovic added: "The breakthrough we achieved will have a dramatic and unprecedented impact on the dairy industry, consumers and the environment. The improvement in milk quality and yield will not only result in better consumption for consumers but will also contribute to more efficient and environmentally friendly milk production processes. Consumers can look forward to a future where They will consume milk richer in proteins and fats, produced from healthier cows – without any harm to the animals."

Ram Sargo, CEO of Strauss' Yatvata Dairies: "In recent years, we have been implementing a sustainable dairy program in our dairy farms, a project that closely examines the way milk is produced from the point of view of sustainability and the welfare of the cow: how it lives, proximity to the cow's natural behavior, cow health, examination The treatments she undergoes, care for the food she eats, the quality of the environment, reducing greenhouse gas emissions and more. The association with the Milotis company with the groundbreaking experiment in the development of the antibiotic substitute, helps us deepen the impact on the welfare of the cows and implement an important part of the sustainability goals in the dairy farms. Indeed, from the reports of the dairy farms that participated, there is a high level of satisfaction with various parameters of the cow's welfare and the quality of the environment, and the dairy farmers even expressed a desire to start using the preparation. We believe that if we act in an appropriate and responsible way in the milk production process, we will be able to give the consumer peace of mind and confidence in our dairy products in regards to our attitude towards cows, our impact on the environment and its natural resources, as well as the desired transparency in all the way the milk went from the field to the plate."

The use of Milotis biological preparation improves the well-being of the cows and reduces their suffering. The significant improvements achieved by the company go beyond the immediate benefits of Imilac™ and the company is in the process of developing additional product lines that address indications other than mastitis. According to the company's assessment, the use of the preparation, along with other technologies that the company is working on, are expected to reduce the use of antibiotics in dairy farms by up to 90%.

Milotis was founded by the company's CEO, David Javier Iskovic, jointly with his father, Dr. Jose Iskovic, an expert epidemiologist, based on the initial technology of the Volcanic Institute, the father's research and the expertise of both. The company employs over 50 employees and is recruiting additional employees.

Milotis has developed a line of biological products based on proteins naturally found in milk. The first product line includes specific peptides (parts of proteins) that increase the activity of the immune system in the fetus and thus make it possible to treat and prevent the disease. The company believes that the Imilac™ product and the company's technology as a whole constitute a revolution in animal health and in the management of udder diseases in the dairy in particular. The rich knowledge gained by Milotis will be used to develop natural biological medicines for humans that will treat and save the lives of millions around the world. The company estimates that its top products have an annual market potential of over $1 billion.


source

Related Breaking News

Latest Headlines

Never Miss the Important Stories

Three quick briefings a day.

The key Israel news you need to know, straight to your inbox.

Free. No spam. Unsubscribe anytime.